85 results about "Sleeping disorders" patented technology

The invention relates to the technical field of medical detection and monitoring, in particular to a neurology patient sleep disorder monitoring method, which comprises the following steps: S1, collecting and preprocessing body signals of a patient; s2, constructing a cross-modal association graph, and forming a heterogeneous graph structure with a time sequence weight and a modal label; s3, performing graph convolution and sparse attention operation on the cross-modal association graph, and executing node screening and edge weight updating; s4, time domain and frequency domain decomposition is carried out, and alignment is carried out based on time and frequency indexes; s5, performing segmentation and boundary calibration on the feature sequence, dividing sleep stages, and indexing and storing cross-modal fragments; s6, retrieving abnormal stage fragments, constructing abnormal feature sub-graphs and executing structure clustering operation; and S7, mapping the sleep disorder category labels and the cross-modal features to generate associated features and output results. According to the method, the cross-modal heterogeneous graph is constructed and the time-frequency features are fused, so that the recognition precision and the analysis depth of the sleep disorder of the patient in the neurology department are improved.

The invention discloses a correlation analysis method for sleep disorder and cardiovascular adverse events of an MINOCA patient, relates to the field of clinical decision of cardiovascular diseases, and aims to perform anti-factual reasoning on data of a specific patient based on a structural causal model and simulate the correlation between sleep disorder and cardiovascular adverse events of the patient under the condition of changing one or more sleep characteristic variables. The theoretical change value of the cardiovascular adverse event risk of the patient is calculated, and the expected risk reduction benefit of intervention is calculated; and generating a decision support report, and performing visual display. According to the method, by means of time sequence causal discovery and a structural causal model, the causal relationship and effect quantification of sleep features, intermediary indexes and adverse events are defined, and a core action mechanism is revealed; a personalized intervention effect is simulated through anti-factual reasoning, and a precise risk prediction and intervention basis is provided for clinic; the visual decision support report reduces the clinical application threshold, assists in optimizing the personalized treatment scheme of the MINOCA patient, and effectively reduces the risk of cardiovascular adverse events.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

The invention relates to a composition with sleep aiding and skin repairing effects and a preparation method and application thereof, and belongs to the technical field of cosmetics. The invention provides a composition with sleep aiding and skin repairing effects. The composition is prepared from the following components in parts by weight: 72 to 114 parts of compound plant essential oil, 3 to 5 parts of ceramide NP and 1 to 3 parts of sodium hyaluronate, the compound plant essential oil is prepared from lavender essential oil, sweet orange essential oil, chamomile essential oil, rosemary essential oil and rhodiola rosea essential oil; the rhodiola rosea essential oil is obtained by fermenting a mixed strain composed of kluyveromyces lactis and trichoderma asperellum and then extracting essential oil. The research shows that the mixed strain fermentation can synergistically improve the extraction rate of the rhodiola rosea essential oil. In addition, the compound plant essential oil provided by the invention can also synergistically improve the anti-inflammatory, moisturizing and anti-allergy repair capabilities of the composition and has the effect of improving sleep disorders, so that the composition has better sleep aiding and skin repairing effects at the same time.

The invention relates to an application of propylamine bromide (C23H30BrNO3) in the treatment of sleep disorder, in particular to an application of propylamine bromide (C23H30BrNO3) in the treatment of sleep disorder. Existing sleep drugs are generally ineffective to sleep disorders related to circadian rhythm, and benzodiazepine and non-benzodiazepine hypnotics have significant side effects such as dependency, cognitive disorder and dizziness, so that long-term use of the traditional sleep drugs is limited. According to the invention, a per3 gene defect zebrafish model is used for drug screening, and a new application of a clinically used drug, namely propylamine bromide, in preparation of drugs for treating sleep disorders is provided for the first time, especially those which are insensitive to existing sedative drugs or related to circadian rhythm disorder, and have no toxic or side effects on sleep disorders. The optimal curative effect can be achieved in the indications by 20 mu M, the sleep-awakening cycle disorder caused by PER3 defects is improved, and the normal sleep-awakening cycle is recovered.

The invention discloses an application of a CHRNA3 agonist in treatment of sleep disorders. The application finds that the CHRNA3 agonist varenicline can effectively relieve the sleep disorder reaction for the first time, on this basis, the invention provides a new application of the CHRNA3 agonist varenicline in treating the sleep disorder, and meanwhile, provides a method for screening candidate drugs for treating diseases caused by hypoxia stress, and provides a new application of the CHRNA3 agonist varenicline in treating the sleep disorder. A new treatment means is provided for sleep disorder, especially sleep disorder caused by hypoxia stress.

The present disclosure relates to a composition for preventing, ameliorating or treating sleep disorder or insomnia, which contains an extract of a roasted citrus byproduct as an active ingredient. The extract of a roasted citrus byproduct of the present disclosure has very excellent effect of decreasing sleep latency, increasing sleep duration and increasing non-REM sleep. In addition, the composition of the present disclosure, which contains ingredients derived from the naturally occurring citrus byproduct, can ensure safety without inducing the side effects of synthetic drugs including pentobarbital and benzodiazepine and with no side effects such as cognitive impairment, tolerance or dependency even after long-term use. Accordingly, the composition for preventing, alleviating or treating sleep disorder, which contains an extract of a roasted citrus byproduct as an active ingredient, of the present disclosure is very useful for preparation of a food composition and a pharmaceutical composition.

The application discloses a traditional Chinese medicine composition for treating postprandial discomfort syndrome with sleep disorder, which comprises the following components in parts by weight: 15-20 parts of Radix Bupleuri, 15-20 parts of Rhizoma Atractylodis Macrocephalae, 20-25 parts of Radix Codonopsis, 10-15 parts of Fructus Aurantii Immaturus, 15-20 parts of Radix Paeoniae Alba, 10-15 parts of Pericarpium Citri Reticulatae, 10-15 parts of Rhizoma Pinelliae Praeparatum, 10-15 parts of Radix Salviae Miltiorrhizae, 10-15 parts of Fructus Amomi Rotundus, and 10-15 parts of Radix Glycyrrhizae Praeparata Cum Melle. The traditional Chinese medicine composition has the effects of soothing liver and invigorating spleen, regulating qi and adjusting center, and has good effects on improving symptoms such as upper abdominal pain and postprandial fullness, and has good safety. Meanwhile, the traditional Chinese medicine composition can effectively relieve symptoms such as anxiety and depression caused by gastrointestinal discomfort, and has remarkable curative effects on postprandial discomfort syndrome with sleep disorder.

The present patent application discloses an antidepressant composition containing rare ginsenosides and a preparation method thereof. The antidepressant composition of the present application contains ginseng hydrolysate, Zizyphus jujuba powder and gamma-aminobutyric acid and other functional ingredients, wherein the ginseng hydrolysate is rich in rare ginsenoside CK. The antidepressant composition of the present application has good antidepressant efficacy, can significantly increase the content of 5-hydroxytryptophan (5-HT) and gamma-aminobutyric acid (GABA) in brain tissue, achieve better enhancement of emotional stability and cognitive flexibility, improve anhedonia, relieve anxiety comorbidity and sleep disorders, provide a steady-state foundation for emotional recovery, and improve the efficacy of antidepressants. At the same time, the antidepressant composition of the present application has no side effects on the human body, the product has high safety, the preparation method is simple, the quality is controllable, and the industrialized continuous production can be realized.

The invention relates to the technical field of medicines, health care products and functional foods, and particularly discloses an anti-osteoporosis natural product composition based on sleep disorder symptom improvement. The composition comprises 20-40 parts of a component A, 10-50 parts of a component B and 30-40 parts of a component C, the component A comprises 0.1-1.0 part of melatonin, 5-9 parts of lyophilized powder of Yunnan elaeagnus elaphus, 5-10 parts of yam flour and 5-20 parts of millet flour; the component B is prepared from 5 to 25 parts of royal jelly freeze-dried powder, 3 to 24 parts of pollen aqueous extract and 0.001 to 0.05 part of vitamin K2; the component C is prepared from 5 to 10 parts of ganoderma lucidum spore powder, 10 to 25 parts of shrimp shell powder, 10 to 20 parts of blueberry freeze-dried powder and 0.001 to 0.005 part of vitamin D3. The composition is designed by taking improvement of sleep disorder as a key entry point for preventing and treating osteoporosis, and the limitation that only local or single factors of bone metabolism are concerned traditionally is broken through.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Systems, devices, and methods are provided for performing a sleep study of a subject. The methods include obtaining data from one or more body signals, the one or more body signals being non-brain signals, and determining an arousal or arousal-associated event of the subject using the data from one or more body signals. In a preferred embodiment, the one or more body signals include data obtained from one or more RIP belts.

The invention belongs to the field of transdermal drug delivery materials, and provides a high-molecular sustained-release material for sleep disorders and a preparation method of the high-molecular sustained-release material. The design that a star-shaped polyurethane-silane prepolymer is self-assembled in an ethanol-water mixed solvent to form nano-micelles, melatonin is loaded, and a Si-O-Si cross-linked stable structure is formed on a shell layer through hydrolytic condensation of triethoxysilane is adopted, the median particle size of the obtained nano-dispersion system is 80-200 nanometers, the drug loading capacity is 5-20%, and the stability of the melatonin is improved. And propylene glycol is used as a penetration enhancer to form a coating transdermal drug delivery preparation. The synergistic improvement of low viscosity, coating processability, shell crosslinking stability, drug sustained release and transdermal permeability under high solid content is realized. The problem that an existing nano-micelle film-forming type percutaneous dispersion system is difficult to give consideration to coupling contradictions of a processing window, drug release permeability and safety is solved, and the nano-micelle film-forming type percutaneous dispersion system has wide application value in the field of sleep disorder percutaneous treatment.

The present invention relates to an integrated sleep diagnosis and treatment device, and more particularly to an integrated apnea diagnosis and treatment device. The present invention additionally relates to methods of sleep diagnosis and treatment. The sleep disorder treatment system of the present invention can use a diagnosis device to perform various forms of analysis to determine or diagnose a subject's sleeping disorder or symptoms of a subject's sleep disorder, and using this analysis or diagnosis can with or in some embodiments without human intervention treat the subject either physically or chemically to improve the sleeping disorder or the symptoms of the sleeping disorder. The diagnostic part of the system can use many different types of sensors and methods for diagnosing the severity of the symptoms of or the sleep disorder itself. The treatment part of the system can use a device to physically or chemically treat the subject's symptoms or sleep disorder itself.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

The invention relates to application of arachidonic acid (ARA) in preparation of a medicine for treating sleep disorder related spontaneous abortion. Peripheral blood lipid metabolism sequencing analysis finds that the ARA content in peripheral blood serum of a patient suffering from sleep disorder and repeated pregnancy loss is most obviously reduced compared with that of a patient suffering from normal sleep and normal pregnancy; an enzyme-linked immunosorbent assay test shows that the content of ARA in decidua stromal cells (DSCs) of a patient with sleep disorder and repeated pregnancy loss is remarkably reduced compared with that of a pregnant person with normal sleep; after the endometrial stromal cells (ESCs) are subjected to ARA treatment, the in-vitro decidualization level is increased; the ARA inhibitor can be used for inhibiting the in-vitro deciduation level of the ESCs; compared with a mouse with normal sleep, the content of ARA in peripheral blood and DSCs of a mouse with sleep disorder is remarkably reduced, decidua is poor, and the abortion rate is increased; supplementing ARA can improve decidua disorder and high abortion rate caused by sleep disorder. Therefore, a potential target and a new idea are provided for diagnosis and treatment of repeated pregnancy loss related to sleep disorder.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

This invention relates to the field of microbial pharmaceutical technology, specifically disclosing the application of *Blautia Obeum* in the preparation of drugs for the prevention and treatment of depression, representing a novel use of probiotics for antidepressant purposes. This invention is the first to apply *Blautia Obeum* to the prevention and treatment of depression. This strain can be prepared in various forms, including live bacterial preparations, inactivated bacterial cells, bacterial lysates, metabolites, or bacterial extracts, combined with pharmaceutically acceptable excipients to formulate various oral microecological preparations, including conventional dosage forms such as tablets, capsules, enteric-coated preparations, and oral liquids. The drugs can effectively improve core clinical symptoms of depression, such as low mood, loss of interest, sleep disorders, anxiety, and irritability, by regulating intestinal flora homeostasis, repairing intestinal barrier function, and modulating the brain-gut axis signaling pathway. It is suitable for the prevention and treatment of various types of depression, including major depressive disorder, postpartum depression, geriatric depression, and chronic stress-induced depression. The strain used in this invention is safe and highly compatible, and the preparation is convenient to administer, providing a novel microecological intervention scheme for the clinical prevention and treatment of depression, overcoming some limitations of existing antidepressant methods, and possessing good prospects for pharmaceutical development.

This invention provides a multi-dimensional monitoring and assessment method for sleep disorders at high altitudes, comprising: S1, concurrently collecting respiratory signals, blood oxygen saturation and pulse wave (PPG), heart rate / ECG, body movement and position, and environmental parameters such as altitude / air pressure and temperature and humidity during nighttime sleep; S3, performing sleep / wake discrimination and detecting apnea, hypoventilation, and blood oxygen desaturation events based on structured data, and statistically analyzing event metrics; S4, calculating the frequency domain characteristics of heart rate variability (HRV) from RR interval sequences to obtain a sympathetic nerve activity proxy index; S5, weightedly fusing the event metrics, oxygenation metrics, and sympathetic proxy into a comprehensive score R and performing hierarchical interpretation; S6, fitting an individualized risk trajectory model to the cross-night scoring sequence and outputting short-term predictions. This method enables the construction of individualized adaptation trajectories and short-term prediction models in a real-world high-altitude environment, shifting from "static results" to "process evaluation."

Described are compositions comprising a compound of formula I: in which R represents H, or optionally substituted C1-15 alkyl, C1-15 alkenyl or C1-15 alkynyl; or a pharmaceutically acceptable salt, solvate, metabolite, prodrug, bioisostere, or protected form thereof, for use in the treatment or prevention of a sleep disorder, together with methods of treating or preventing a sleep disorder in a subject or of treating or preventing a symptom or co-morbidity associated with a sleep disorder.

This invention discloses the use of Chek2 inhibitors in the preparation of drugs for the prevention and / or treatment of postoperative pain sensitization induced or aggravated by chronic sleep disorders, and its intervention methods, relating to the field of biomedical technology. This invention provides the use of Chek2 inhibitors in the preparation of drugs for the prevention and / or treatment of postoperative pain sensitization induced or aggravated by chronic sleep disorders. This invention is the first to discover and validate Chek2 as a key molecular target linking "chronic sleep disorders" and "postoperative pain sensitization." By constructing a composite animal model of chronic sleep deprivation (CSD) combined with postoperative incision pain, the pathological process of increased postoperative pain in patients with sleep disorders was simulated. Using mRNA-seq and Western blot techniques, this invention is the first to discover and confirm that the expression level of Chek2 in the nucleus accumbens (NAc) brain region is significantly upregulated during postoperative pain sensitization induced by chronic sleep disorders, filling a gap in the field of "sleep disorder-pain interaction" regarding specific central targets.

A method according to the present disclosure improves sleep states, maintains a sound sleep, restores the balance of gut microbiota disrupted by sleep disorders, and supports the management of health including metabolic syndrome. Under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, the Limosilactobacillus reuteri LM1063 strain was deposited with the international depositary authority: the Korean Collection for Type Cultures on Mar. 23, 2017, under the Accession Number: KCTC 13232BP.

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.

The invention relates to the fields of biotechnology, traditional Chinese medicines and nutritional health-care products, in particular to a bifidobacterium breve-containing medicinal and edible composite composition and application thereof in preparation of products for preventing or treating anxiety and depression, improving sleep disorders and assisting in weight management. The composite composition is prepared from bifidobacterium breve and a medicinal and edible composition, and the ratio of the bifidobacterium breve to the medicinal and edible composition is 1 * 10 < 10 > CFU of the bifidobacterium breve and 60 g of the medicinal and edible composition. The composition disclosed by the invention has a remarkable synergistic effect, can effectively prevent or relieve anxiety and depression symptoms, can improve sleep quality, and can assist in reducing body weight and body fat. The action mechanism relates to double targets of'intestine-brain-metabolic axis', and the double targets supplement each other to synergistically promote nerve-immunity-endocrine and metabolic balance. The composition disclosed by the invention can be used for preparing medicines, functional foods or health-care products, and provides a safe and effective brand-new choice for intervention of multiple health problems (emotion, sleep and metabolic disorders).

The invention relates to an application of atropine (Atropine, C17H23NO3) in preparation of a medicine for treating sleep disorder. Existing sleep drugs are generally ineffective to sleep disorders related to circadian rhythm and cannot restore a normal sleep-awakening period for many patients, and benzodiazepine and non-benzodiazepine hypnotics have significant side effects such as dependency, cognitive disorder and dizziness, and long-term use of the drugs is limited. According to the invention, a per3 gene defect zebrafish model is used for drug screening, and a new application of a clinically used drug, namely atropine, in preparation of drugs for treating sleep disorders is provided for the first time, especially for treating sleep disorders which are insensitive to existing sedative drugs or are related to circadian rhythm disorder, and particularly for treating sleep disorders which are not sensitive to existing sedative drugs or are related to circadian rhythm disorder, circadian rhythm disorder, circadian rhythm disorder and circadian rhythm disorder. The optimal curative effect can be achieved in the indication by 12 mu M, the sleep-awakening cycle disorder caused by Per3 defects is improved, and the normal sleep-awakening cycle is recovered.

Provided are systems, methods, and devices for providing mediation or alleviation of sleep disorders and insomnia. Systems may include an interface, processing devices, and a controller. The interface is configured to obtain measurements from a brain of a user with sleeping disorders and insomnia. A first processing device is configured to generate multiple brain state parameters characterizing one or more features of a brain state of the user. A second processing device is configured to generate models of the brain of the user based on the plurality of brain state parameters and the plurality of measurements, and determine, using the models and training data comprising one or more mediation data points, a mediation procedure for reducing one or more symptoms of the sleeping disorder or insomnia. The mediation procedure is provided to one or more entities, and one or more control signals are generated by the controller based on the mediation procedure.